(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators ... based on research showing the medicine, called inavolisib, could ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy inavolisib ... the evaluation and review processes for certain therapies.

Roche has claimed a breakthrough ... HER2-negative breast cancer. That same month, Datroway was granted priority review by the FDA for EGFR-mutated NSCLC—which analysts have described as the ...

As Roche pointed out, Starglo is the first randomized phase 3 study in second-line transplant-ineligible DLBCL to show an overall survival improvement. The FDA ... to Cancer Science and Medicine ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer. Among patients with liver-dominant metastatic ...

A study involving an experimental cancer drug being developed by Roche ... HER2-positive breast cancer," said Kimberly Blackwell, the study's lead researcher and a professor of medicine at Duke ...

Roche received FDA clearance last year for the test to be used in the United States. More than 90% of cervical cancer cases are caused by HPV, according to the U.S. Centers for Disease Control and ...